• Something wrong with this record ?

Promises and Challenges of Immunogenic Chemotherapy in Multiple Myeloma

M. Johnstone, D. Vinaixa, M. Turi, E. Morelli, KC. Anderson, A. Gulla

. 2022 ; 11 (16) : . [pub] 20220814

Language English Country Switzerland

Document type Journal Article, Review

Persistent link   https://www.medvik.cz/link/bmc22024838

Grant support
SPORE-P50CA100707 NIH HHS - United States
R01-CA050947 NIH HHS - United States
R01CA207237 NIH HHS - United States
P01CA155258 NIH HHS - United States
5R25CA174650 NCI NIH HHS - United States
n/a International Myeloma Foundation
SPORE-P50CA100707 Dana-Farber/Harvard Cancer Center
n/a Leukemia and Lymphoma Society
n/a American Society of Hematology

Immunological tolerance of myeloma cells represents a critical obstacle in achieving long-term disease-free survival for multiple myeloma (MM) patients. Over the past two decades, remarkable preclinical efforts to understand MM biology have led to the clinical approval of several targeted and immunotherapeutic agents. Among them, it is now clear that chemotherapy can also make cancer cells "visible" to the immune system and thus reactivate anti-tumor immunity. This knowledge represents an important resource in the treatment paradigm of MM, whereas immune dysfunction constitutes a clear obstacle to the cure of the disease. In this review, we highlight the importance of defining the immunological effects of chemotherapy in MM with the goal of enhancing the clinical management of patients. This area of investigation will open new avenues of research to identify novel immunogenic anti-MM agents and inform the optimal integration of chemotherapy with immunotherapy.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22024838
003      
CZ-PrNML
005      
20221031100555.0
007      
ta
008      
221017s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/cells11162519 $2 doi
035    __
$a (PubMed)36010596
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Johnstone, Megan $u Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Boston, MA 02215, USA
245    10
$a Promises and Challenges of Immunogenic Chemotherapy in Multiple Myeloma / $c M. Johnstone, D. Vinaixa, M. Turi, E. Morelli, KC. Anderson, A. Gulla
520    9_
$a Immunological tolerance of myeloma cells represents a critical obstacle in achieving long-term disease-free survival for multiple myeloma (MM) patients. Over the past two decades, remarkable preclinical efforts to understand MM biology have led to the clinical approval of several targeted and immunotherapeutic agents. Among them, it is now clear that chemotherapy can also make cancer cells "visible" to the immune system and thus reactivate anti-tumor immunity. This knowledge represents an important resource in the treatment paradigm of MM, whereas immune dysfunction constitutes a clear obstacle to the cure of the disease. In this review, we highlight the importance of defining the immunological effects of chemotherapy in MM with the goal of enhancing the clinical management of patients. This area of investigation will open new avenues of research to identify novel immunogenic anti-MM agents and inform the optimal integration of chemotherapy with immunotherapy.
650    _2
$a lidé $7 D006801
650    _2
$a imunoterapie $7 D007167
650    12
$a mnohočetný myelom $7 D009101
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Vinaixa, Delaney $u Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Boston, MA 02215, USA $1 https://orcid.org/0000000334983669
700    1_
$a Turi, Marcello $u Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Boston, MA 02215, USA $u Faculty of Science, University of Ostrava, 70100 Ostrava, Czech Republic $u Faculty of Medicine, University of Ostrava, 70300 Ostrava, Czech Republic $u Department of Hematooncology, University Hospital Ostrava, 70800 Ostrava, Czech Republic $1 https://orcid.org/0000000287601794
700    1_
$a Morelli, Eugenio $u Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Boston, MA 02215, USA $u Harvard Medical School, Boston, MA 02115, USA
700    1_
$a Anderson, Kenneth Carl $u Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Boston, MA 02215, USA $u Harvard Medical School, Boston, MA 02115, USA
700    1_
$a Gulla, Annamaria $u Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Boston, MA 02215, USA $u Harvard Medical School, Boston, MA 02115, USA
773    0_
$w MED00194911 $t Cells $x 2073-4409 $g Roč. 11, č. 16 (2022)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36010596 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20221031100552 $b ABA008
999    __
$a ok $b bmc $g 1854517 $s 1176128
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 11 $c 16 $e 20220814 $i 2073-4409 $m Cells $n Cells $x MED00194911
GRA    __
$a SPORE-P50CA100707 $p NIH HHS $2 United States
GRA    __
$a R01-CA050947 $p NIH HHS $2 United States
GRA    __
$a R01CA207237 $p NIH HHS $2 United States
GRA    __
$a P01CA155258 $p NIH HHS $2 United States
GRA    __
$a 5R25CA174650 $p NCI NIH HHS $2 United States
GRA    __
$a n/a $p International Myeloma Foundation
GRA    __
$a SPORE-P50CA100707 $p Dana-Farber/Harvard Cancer Center
GRA    __
$a n/a $p Leukemia and Lymphoma Society
GRA    __
$a n/a $p American Society of Hematology
LZP    __
$a Pubmed-20221017

Find record

Citation metrics

Archiving options